Carfilzomib-based treatment improves outcomes in multiple myeloma
- Carfilzomib-based treatment improves outcomes in multiple myeloma
- Genome sequencing may guide treatment across solid cancers
- Sickle cell mice showed blood changes linked to acute myeloid leukemia
Carfilzomib-based treatment improves outcomes in multiple myeloma
In a phase 2 trial, people with newly diagnosed multiple myeloma who could have a transplant received a carfilzomib-based combination with or without a transplant. Cancer growth was delayed for 98 months with a transplant, versus 70 months without one.
“In conclusion, long-term follow-up confirms the high effectiveness of KRd-ASCT and KR maintenance.”
Why it matters. People with newly diagnosed multiple myeloma who can have a transplant may have more time before their cancer grows. A larger trial usually comes before approval.
Blood, 16 Nov 2026 · Phase II human clinical trial Worth sharing · Share on X · Email a friendGenome sequencing may guide treatment across solid cancers
A retrospective analysis across solid cancers found that whole-genome sequencing can identify possible targets for targeted drugs. Trials are needed to learn whether these findings can expand treatment beyond current cancer-specific uses.
“Our findings support comprehensive whole-genome sequencing assessment of cancers irrespective of tumour type.”
Why it matters. People with solid cancers may one day get targeted drugs chosen from whole-genome sequencing results. It studied patient records rather than testing a treatment.
The Lancet Oncology, 16 Nov 2026 · Human observational studySickle cell mice showed blood changes linked to acute myeloid leukemia
Researchers tracked blood changes in sickle cell mice and found more abnormal blood-cell growth and cancer-linked cell clones. Repeated stem cell transplants increased the number of these clones.
“Our study provides insights into a mechanism underlying increased risk of HM in this non-malignant hematological disorder, and suggests that early intervention with curative therapies may circumvent this risk.”
Why it matters. This could one day help people with sickle cell disease avoid blood cancers linked to abnormal blood-cell growth. This lab work is years from patients.
Blood, 16 Nov 2026 · Translational research (lab work plus patient samples)Deals and stopped trials
- STAT+: FDA approves new breast cancer drug, providing new option for some patients, boost for Rochestatnews.com
- AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)Terminated · Phase I/II · Arsenal Biosciences, Inc. · Reason given: Sponsor decision
- Study of NMS-03305293 in Adult Patients With Relapsed Ovarian CancerTerminated · Phase I · Nerviano Medical Sciences · Reason given: The decision about study closure has not been based on safety profile or clinical data of NMS-03305293 but a strategic decision driven by changes in the treatment landscape and anticipated significant delays in patient enrollment.
- KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast CancerPhase II · Beijing Konruns Pharmaceutical Co., Ltd. · earlier phase I: NCT07118709
India
New trials
- A Vaccine (Nous-209) for the Reduction of Colorectal Lesion Size in Patients With Lynch SyndromeCancer vaccines · Phase II · 55 people · National Cancer Institute (NCI) · United States
Worth watching
- Genome sequencing may find treatment targets across solid cancersResearchers reviewed whole-genome sequencing across solid cancers. They say it may find treatment targets, but trials must show whether this can expand use of targeted drugs.
- The bispecific antibody etentamig showed responses in multiple myelomaA phase 1 study tested the bispecific antibody etentamig in 146 people with relapsed or hard-to-treat multiple myeloma. Their cancer responded to treatment in 66% of cases.
- Brain tumor classification from contrast-enhanced T1 MRI, a patient-wise deep learning studyResearch finding, Scientific Reports, 16 Nov 2026